Biogen (BIIB) Earnings Analysis

Biogen (BIIB) next reports earnings on 2026-07-29, consensus EPS 3.15 USD. Last quarter (2026-02-06) it beat with EPS 1.99 USD vs 1.63 USD est (+22.1%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 21.10.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BIIB next report earnings?

Next earnings date2026-07-29
Consensus EPS estimate3.15 USD
Revenue estimate2.46B

BIIB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-061.99 USD1.63 USD+22.1%Beat
2025-10-304.81 USD3.88 USD+24%Beat
2025-07-315.47 USD3.9 USD+40.3%Beat
2025-05-013.02 USD2.9 USD+4.1%Beat
2025-02-123.44 USD3.43 USD+0.3%Beat
2024-08-015.28 USD4.07 USD+29.7%Beat

Beat rate: 6/6 (100%) over reported quarters with consensus data.

BIIB valuation and analyst view

Trailing P/E21.10
Trailing EPS9.323 USD
Price / book1.56
Dividend yield0.00%
Market cap29.65B
Analyst consensusBuy (30 buy / 17 hold / 1 sell)
Avg price target224.87 USD

Related research pages

Frequently asked questions

When is Biogen (BIIB)'s next earnings date?

Biogen is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 3.15 USD and revenue estimate of 2.46B.

Did BIIB beat earnings last quarter?

In its 2026-02-06 report, BIIB posted EPS of 1.99 USD versus a 1.63 USD estimate — a beat of 22.1%.

What is BIIB's earnings track record?

Over the last 6 reported quarters with consensus data, BIIB beat estimates 6 times (100%).

What is BIIB's current P/E ratio and EPS?

BIIB trades at a trailing P/E of 21.10 on trailing EPS of 9.323294836956523 USD.

What do analysts rate BIIB?

Analyst consensus is "Buy" across 48 ratings (0 strong buy, 30 buy, 17 hold, 1 sell, 0 strong sell). Average 12-month price target: 224.87 USD.